Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Oncodesign, Sanofi Sign Second Kinase Inhibitor Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Oncodesign, Sanofi Sign Second Kinase Inhibitor Pact

Aims to identify inhibitors that play a role in tissue protection and repair

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Oncodesign, a provider of pharmacological evaluation services, has entered its second research collaboration agreement with Sanofi relating to several kinase targets being developed by Sanofi.  This second agreement aims to identify inhibitors of a kinase that plays a key role in tissue protection and repair. Financial details were not disclosed.
 
Oncodesign will use its Nanocyclix technology to design and synthesize potent new selective inhibitors. Sanofi will be responsible for the cost of the initial phase of the work and will have exclusive licensing rights to the molecules that result from the collaboration.
 
“This new agreement with Sanofi demonstrates the level of interest in our Nanocyclix technology from some of the most well-renowned pharma companies. This is our third collaboration agreement in a year of drug discovery, establishing our company as a leader in the field of kinase inhibitors in a variety of therapeutic areas,” said Dr. Philippe Genne, chairman, chief executive officer and founder of Oncodesign.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics